MoonLake Immunotherapeutics’s recently made public that its Director BVF PARTNERS L P/IL unloaded Company’s shares for reported $100.0 million on Oct 04 ’24. In the deal valued at $50.00 per share,2,000,000 shares were sold. As a result of this transaction, BVF PARTNERS L P/IL now holds 1,287,768 shares worth roughly $50.31 million.
Then, Sturge Simon sold 171,000 shares, generating $9,186,120 in total proceeds. Upon selling the shares at $53.72, the Director now owns 171,980 shares.
RBC Capital Mkts initiated its MoonLake Immunotherapeutics [MLTX] rating to an Outperform in a research note published on March 18, 2025; the price target was $67. A number of analysts have revised their coverage, including Goldman’s analysts, who increased its forecast for the stock in mid January from “a Neutral” to “a Buy”. Wolfe Research revised its rating on August 26, 2024. It rated MLTX as “a Peer perform” which previously was an “an Outperform”.
Price Performance Review of MLTX
On Monday, MoonLake Immunotherapeutics [NASDAQ:MLTX] saw its stock fall -1.98% to $39.07. Over the last five days, the stock has lost -3.71%. MoonLake Immunotherapeutics shares have fallen nearly -27.85% since the year began. Nevertheless, the stocks have fallen -22.19% over the past one year. While a 52-week high of $58.26 was reached on 01/02/25, a 52-week low of $36.52 was recorded on 03/11/25. SMA at 50 days reached $42.09, while 200 days put it at $46.71.
Levels Of Support And Resistance For MLTX Stock
The 24-hour chart illustrates a support level at 37.32, which if violated will result in even more drops to 35.58. On the upside, there is a resistance level at 40.75. A further resistance level may holdings at 42.43. The Relative Strength Index (RSI) on the 14-day chart is 44.26, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.15, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 63.80%. Stochastics %K at 50.71% indicates the stock is a holding.
How much short interest is there in MoonLake Immunotherapeutics?
A steep rise in short interest was recorded in MoonLake Immunotherapeutics stocks on 2025-03-14, dropping by -0.81 million shares to a total of 7.24 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 8.05 million shares. There was a decline of -11.13%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on June 25, 2024 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $104 price target.
